Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Encorafenib | Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival. Synonyms: LGX818; LGX-818; LGX 818; Methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate. Grades: ≥98%. CAS No. 1269440-17-6. Molecular formula: C22H27ClFN7O4S. Mole weight: 540.011. |  |
| Encorafenib | Encorafenib Inhibitor. Uses: Scientific use. Product Category: T6487. CAS No. 1269440-17-6. |  |
| Encorafenib | Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAF V600E ( EC 50 =4 nM). Uses: Scientific research. Group: Signaling pathways. Alternative Names: LGX818. CAS No. 1269440-17-6. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15605. |  |
| (R)-Encorafenib | Encorafenib is a Proto oncogene protein b raf inhibitor with potential antineoplastic activity. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of Encorafenib may result in a decrease in proliferation of tumor cells. Now, treatment for Colorectal cancer and Malignant melanoma is in clinical trials Phase III. Treatment for Multiple myeloma and Solid tumours is in clinical trials Phase II. Uses: Colorectal cancer; malignant melanoma;multiple myeloma; solid tumours. Synonyms: LGX818; LGX 818; LGX-818; UNII-8L7891MRB6; methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate;1269440-29-0 (R-isomer of LGX-818). Grades: 98%. CAS No. 1269440-29-0. Molecular formula: C22H27ClFN7O4S. Mole weight: 540.01. | |
Our database is helping our users find suppliers everyday.
